MedPal AI (MPAL ) reported a stronger December 2025 for its automated pharmacy operations, while also highlighting the US FDA approval of Novo Nordisk’s oral Wegovy for weight management.
During December 2025, MedPal processed 33,433 prescription orders, generating turnover of about £325,000 at an average item value of £9.72. This was around 16% higher than November 2025’s 28,789 prescriptions, despite the shorter trading month over the Christmas period.
The company said prescription growth reflects the ongoing integration of its National Health Service (NHS) Distance Selling Pharmacy (DSP) contract and increasing uptake of its private weight loss service, launched via MedPal.clinic.
Meanwhile, MedPal noted that on 22 December 2025 the FDA approved Novo Nordisk’s Wegovy pill (oral semaglutide 25 milligram), which it described as the first oral glucagon-like peptide-1 (GLP-1) medicine approved for weight management. The company said the approval provides a once-daily pill alternative to weekly injections.
MedPal added that clinical trials showed weight loss of up to 16.6% in adherent patients over 64 weeks, which it said was comparable to the injectable form. The company believes wider adoption could follow, as an oral option may reduce barriers associated with injections.
MedPal’s CEO Jason Drummond said: “We are delighted with MedPal Limited's continued strong performance, achieving 16% month-on-month growth despite the Christmas period shortening our effective trading days. Processing approximately 33,000 prescriptions in December demonstrates the scalability and resilience of our automated dispensing infrastructure.
“We were also pleased to hear of the FDA's approval of the first oral GLP-1 for weight loss, which we expect to be transformative for the industry. By removing the barrier of injectable administration, we anticipate significant expansion of the patient population seeking treatment. MedPal.clinic's AI-first approach positions us to efficiently serve this growing market whilst maintaining the highest standards of clinical safety and patient care.”
View from Vox
December’s step-up in prescription volumes suggests MedPal’s pharmacy platform is scaling, with the NHS DSP contract and private weight loss service both pointed to as drivers. Going forward, an oral GLP-1 approval could broaden demand for weight management prescriptions, which may play to MedPal’s model if it can convert interest into repeatable, compliant fulfilment.